Register
Login:
Share:
Email Facebook Twitter




Summit Ther Share Price (SUMM)



Share Price Information for Summit Ther (SUMM)


Share Price: 127.50Bid: 125.00Ask: 130.00Change: 0.00 (0.00%)No Movement on Summit Ther
Spread: 5.00Spread as %: 4.00%Open: 132.50High: 132.50Low: 125.00Yesterday’s Close: 127.50

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
127.50

Share Price SpacerBid
125.00

Share Price SpacerAsk
130.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
68,705

Share Price SpacerOpen
132.50

Share Price SpacerHigh
132.50

Share Price SpacerLow
125.00

Share Price SpacerClose
127.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 61.47m £78.37m 2,000

52 Week High 172.50 52 Week High Date 17-AUG-2015
52 Week Low 82.50 52 Week Low Date 4-MAR-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
25 24,948 33,240 -4.397 -29.00 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

29-Apr-16
16:31:45
127.00
2,500
Sell* 
125.00
130.00
3,175
Trade Type:
Ordinary

29-Apr-16
16:23:03
129.00
5,000
Buy* 
125.00
130.00
6,450
Trade Type:
Ordinary

29-Apr-16
16:22:56
129.00
5,000
Buy* 
125.00
129.00
6,450
Trade Type:
Ordinary




View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
2.33USD7,5007500
17-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
2.3USD10,50010500
16-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
2.34USD4,25014442
View more Summit Ther directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Sat 14:18JolondGood coverage127.50Strong Buy
UK-based Summit Therapeutics (NASDAQ:SMMT) has a bit of good news for Duchenne muscular dystrophy (DMD) investors who are about to bloodied today if they are holding shares in Sarepta Therapeutics (NASDAQ:SRPT). The FDA has cleared its Investigational New Drug (IND) application for DMD candidate ezutromid (formerly SMT C1100) which clears the way to recruit U.S. trial sites in its Phase 2 proof-of-concept study called PhaseOut DMD. The 48-week open-label study, initiated in the UK in January… Read More
Sat 12:50gmccgenerations utrophin modulators127.50No Opinion
Good to see second and third utrophin modulators meriting internal university reviews – Summit next DMD generation drugs in good hands !

FYI : “optimising second and third generations utrophin modulators with improved physicochemical properties and a more robust metabolism profile

Speaker: Dr Simon Guiraud (DPAG, University of Oxford) Organising department: Department of Physiology, Anatomy and Genetics (DPAG)

Date: 27 May 2016, 13:30 (Friday, 5th week, Trinity… Read More
Fri 19:59gmccSUMM127.50No Opinion
Nice upbeat board & good news flow this week thanks everyone !

Even Summit getting in on the act.

https://twitter.com/summitplc

Great to see gradual market cap value improvement , slowly getting there , take a while longer but with two promising drug assets 2016 might just be the pivotal year .

Long bank holiday for you workers enjoy your weekend .

Good luck everyone !
Fri 18:15GP68Seeking Alpha127.50Strong Buy
Fri 17:33wildbunchpomander127.50No Opinion
Thought he had said he would not post anymore!
Fri 16:03Free-MoneyRE: What a great week!127.00No Opinion
Agree AMM, Hopefully they'll finally have all their ducks lined up to start the PhaseOut UK trial next week. I got the impression from the last interview it's been hard work to get the three test centres lined up together.

Also the discussions on the C.Diff partnering deal must be well progressed now. Although it's only May next week and I expected them to take until at least June to finalise a deal. Maybe they'll surprise us. I wouldn't have thought either side would want to delay... the… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Summit Ther (SUMM) >>

Please login or register to post a message on Share Chat.






Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.